1.Ryanodine receptor and its significance on forensic medicine
Yanwei JIANG ; Erliang LIU ; Shaohua ZHU
Chinese Journal of Forensic Medicine 1986;0(01):-
Ryanodine receptor is a Ca2+ release channel in cadiocyte.It is reported recently to the obvious change of its function and quantity in such pathological process as the myocardial ischemia and cardiac hypertrophy.These changes will affect the ability of cadiocytes processing intracellular calcium or lead to the calcium overload in the myocardial cells and then induces fatal ventricular arrhythmia,even sudden cardiac death.
2.Dosage effects in treating tiptoe deformity in children with spastic cerebral palsy using botulinum toxin type A
Dengna ZHU ; Ruimin LIU ; Jun WANG ; Junying YUAN ; Fengwei LIU ; Guohui NIU ; Yongqiang GAO ; Wei ZHANG ; Sansong LI ; Yiwen WANG ; Erliang SUN ; Guangyu ZHANG ; Lei YANG ; Yunxia ZHAO ; Mingmei WANG
Chinese Journal of Physical Medicine and Rehabilitation 2020;42(5):424-428
Objective:To observe the clinical efficacy and side effects of injecting different doses of botulinum toxin type A (BTX-A) into children with spastic cerebral palsy (CP) and tiptoe deformity.Methods:A total of 107 children with tiptoe deformity resulting from CP were divided into group A ( n=35), group B ( n=36) and group C ( n=36) using a random number table. Group A received 3u/kg injections of BTX-A, group B received 4u/kg injections and group C received 5u/kg. The injections were guided by color Doppler ultrasound and followed by 4 courses of rehabilitation therapy. Before and 1, 3 and 6 months after the treatment, the modified Tardieu scale (MTS) was used to assess gastrocnemius spasms, while sections D and E of gross motor function scale 88 (GMFM-88) and the pediatric balance scale (PBS) were used to evaluate motor functioning and balance. Any side effects were also observed. Results:After the treatment, improvement was observed in all of the measurements, though there were no significant differences in the degree of improvement nor in the incidence of side effects among the three groups.Conclusions:There is no significant difference in clinical efficacy or side effects involved in using different doses of BTX-A to treat tiptoe deformity in children with spastic cerebral palsy. The recommended dosage is therefore 3u/kg.